Adjuvance Technologies, Inc.
Pipeline
Saponex
Adjuvance is commercializing our lead product Saponex for use in investigational vaccine formulations. Saponex is Adjuvance’s synthetic version of QS-21. Unlike the natural product, Saponex only contains the two molecules responsible for QS-21’s immunostimulatory activity (QS-21-apiose and QS-21-xylose). Although the ratio of apiose:xylose in the natural product is approximately 65:35, Saponex’s synthetic technology allows Adjuvance to provide the two molecules separately or combined in any desired ratio.
TriSST enabled the synthesis of QS-21 and allowed synthetic QS-21 to surpass the pre-clinical stage and progress to testing in humans in an investigational melanoma therapeutic vaccine (NCT00597272, QS-DG). Saponex represents lower cost, equipotency, exquisite purity and a simple, well defined regulatory process for heavily entrenched vaccine studies. We plan to be the first Drug Master File enabled provider of QS-21, via our lead compound Saponex. Saponex can be directly sold to vaccine manufacturers already assessing QS-21 containing vaccines or those interested in incorporating QS-21 into investigational vaccine formulations.
TiterQuil
Although our Titerquil family of adjuvants are also derived from TriSST, unlike Saponex, Titerquil molecules represent novel compositions of matter that do not exist in nature. TiterQuil molecules are created by targeted molecular variations in the QS-21 molecules based upon observed structure-activity relationships.
TiterQuil molecules are also derived from our TriSST platform and we hope to incorporate these novel adjuvants into the developmental pipelines of vaccine manufacturers and developers very soon. We have employed TriSST to create and test numerous new chemical entities in vivo, demonstrating TriSST’s ability to improve efficacy, toxicity, and stability. We plan to continue building on our preclinical work by commencing at least one clinical trial with a TiterQuil adjuvant within the next 1-2 years in a therapeutic vaccine indication and the next 2-3 years in a prophylactic setting with a strategic partner.